1. Home
  2. GECC vs LUNG Comparison

GECC vs LUNG Comparison

Compare GECC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

HOLD

Current Price

$5.95

Market Cap

84.6M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.32

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GECC
LUNG
Founded
2016
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.6M
97.1M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
GECC
LUNG
Price
$5.95
$2.32
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
$10.75
$5.38
AVG Volume (30 Days)
56.4K
840.0K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
22.06%
N/A
EPS Growth
N/A
7.64
EPS
0.41
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
$0.92
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$14.32
N/A
Revenue Growth
N/A
8.01
52 Week Low
$4.63
$1.13
52 Week High
$11.45
$2.89

Technical Indicators

Market Signals
Indicator
GECC
LUNG
Relative Strength Index (RSI) 63.05 66.28
Support Level $5.26 $1.27
Resistance Level $6.46 $2.39
Average True Range (ATR) 0.24 0.22
MACD 0.05 0.02
Stochastic Oscillator 93.34 79.64

Price Performance

Historical Comparison
GECC
LUNG

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: